Abstract 447P
Background
The addition of chemotherapy to Gefitinib improved outcomes in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations in this trial, these results have already been published. Here we analysed the quality of life (QoL) data of patients in this study to determine the impact of the addition of chemotherapy to Gefitinib on QoL.
Methods
This was a phase III randomized trial in treatment-naive patients with advanced NSCLC with an EGFR-sensitizing mutation and ECOG PS of 0 -2 receiving first-line palliative therapy. Patients were randomized 1:1 to receive either gefitinib 250 mg PO once a day (Gef) or gefitinib 250 mg PO once a day with Pemetrexed (500 mg/m2) + Carboplatin (AUC5) IV every 3 weeks for 4 cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]). The primary endpoint was PFS; QoL was a key secondary endpoint. QoL was assessed using the EORTC QLQ C-30 and LC 13 questionnaires and their validated translations. QoL was collected at 2 monthly intervals [60 (+/-15) days]. The mean QoL scores for both arms were plotted and compared between the two arms at each time point using the Mann-Whitney Test. Sensitivity analysis was performed. The mixed linear model analysis is used to study the impact of treatment arms and time on QoL scores while considering participant variability.
Results
In the linear mixed model analysis (LMA), there was no significant impact on the global health status (QL) scores between the 2 arms (p= 0.5007). However, there was a significant change in the global health status scores in both arms over time (p= 0.0420). In the LMA there were no significant differences in the other function scales between the 2 arms. The scores for the symptoms scale had significantly improved for pain (p = 0.0351), dyspnoea (p = 0.0483), diarrhea (p = 0.0243), sore mouth (p = 0.0283), pain in the arm or shoulder (p = 0.0315), pain in other parts (p = 0.0273) improved over time in the Gef+C arm as compared Gef arm.
Conclusions
The addition of chemotherapy to Gefitinib improved survival outcomes (PFS an dOS) without a significant adverse impact on quality of life.
Clinical trial identification
CTRI/2016/08/007149.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tata Memorial Center Research Administration Council and unrestricted educational grants from Dr. Reddy’s Laboratories, Fresenius Kabi India, Alkem Laboratories, Natco Pharma, BDR Pharmaceuticals, and Lung Cancer Consortium India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract